Big Pharma Quality - Customized Approach! Pillar5 Pharma Inc. provides access to safe medications through various partners as a Contract Manufacturing Organization (CMO). Offering excellence in: operations; quality; business; and customer service. Expertise in: solid dose, ophthalmics and analytical services. Further to the acquisition of the former Pfizer plant, this plant has been in operation since 1956. Pillar5 continuously plans expansion of our capabilities in order to provide cost effective solutions to our customers. Pillar5 has obtained $4M in Government Funding in support of our innovative capital and continuous improvement plan over the next 4 years. It has also been successfully inspected by Health Canada in 2015 and the FDA in 2015.
Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016 The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.
James E. Gregory, UPM Pharmaceuticals||October 7, 2015 Pharmaceutical and biopharmaceutical companies large and small are increasingly relying on third-party providers for support at all stages of drug development. To realize efficiencies, they are at the same time reducing the number of suppliers to a preferred few with whom they can form strategic partnerships.
Franklin Spriggs, Stephanie Mowery and Bo Kowalcyk, AIT Bioscience ||October 7, 2015 ADCs are a breakthrough cancer treatment that can deliver cytotoxins directly to cancer cells without the sweeping collateral damage of traditional chemotherapy.